Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564185 | 0.91 | TBXAS1 (0.39) | CYP26A1CYP3A4TBXAS1NOS2KDM5B | |
| SCHEMBL20565461 | 0.85 | KDM5B (0.38) | TBXAS1NOS2KDM5BCYP19A1KDM4E | |
| SCHEMBL20564820 | 0.83 | CYP19A1 (0.38) | CYP26A1CYP3A4TBXAS1NOS2ALKBH1 | |
| SCHEMBL20564651 | 0.81 | CYP26A1 (0.47) | CYP26A1CYP3A4TBXAS1NOS2CYP19A1 | |
| SCHEMBL20564478 | 0.81 | KDM5B (0.37) | KDM5BKMT2ATDP1 | |
| SCHEMBL20564198 | 0.81 | CYP26A1 (0.39) | CYP26A1CYP3A4TBXAS1NOS2CYP19A1 | |
| SCHEMBL20564189 | 0.77 | CYP26A1 (0.49) | CYP26A1CYP3A4TBXAS1NOS2CYP19A1 | |
| SCHEMBL20564907 | 0.75 | KDM4E (0.41) | TBXAS1NOS2CYP19A1KDM4EALDH1A1 | |
| SCHEMBL20565455 | 0.73 | KDM5B (0.36) | KDM5B | |
| SCHEMBL20957912 | 0.72 | CCNC (0.41) | KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018213777-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | CYP26A1 2715/4885CYP3A4 3097/4885TBXAS1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.